Purdue Diversifies Pain Portfolio With VM Pharma Drug
This article was originally published in Scrip
Executive Summary
Purdue Pharma will diversify its pain-focused portfolio by paying up to $213m plus royalties for the right to develop and commercialize VM Pharma's selective tropomyosin receptor kinase A (TrkA) inhibitor VM-902A and associated compounds.